Claims for Patent: 8,470,358

Summary for Patent: 8,470,358

Title:	Nitric oxide generating medical devices
Abstract:	Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided.
Inventor(s):	Glauser; Thierry (Redwood City, CA), Pacetti; Stephen D. (San Jose, CA), Consigny; Paul (San Jose, CA)
Assignee:	Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)
Application Number:	13/276,666
Patent Claims:	1. A medical device comprising a polymer and a metal complex, the metal complex comprising a metal and at least one ligand, wherein: the polymer forms the medical device or a coating of the medical device; the at least one ligand of the metal complex covalently attaches to a surface of the medical device or the coating on the medical device via a spacer, the spacer is a phenyl group, an aryl group, a short chain peptide, a biocompatible oligomer, or a biocompatible polymer functionalized by a reactive group selected from the group consisting of carboxyl, hydroxyl, thiol, amine, acid halide, N-hydroxysuccinimide, acryloyl, and Vinyl sulfone, the polymer is copolymer of monomers selected from 2-hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC), methacrylic acid (MA), and acrylic acid (AA); the metal complex catalyzes the generation of nitric oxide in the blood stream or a tissue adjacent to the medical device; and the medical device is a non-degradable polymer stent. 2. The medical device of claim 1, wherein the nitric oxide is released from a nitrosylated biomolecule present in the blood stream or a tissue adjacent to the medical device. 3. The medical device of claim 1, wherein the nitric oxide is released from a nitrosylated protein or S-nitrosothiol present in the blood stream or a tissue adjacent to the medical device. 4. The medical device of claim 1, wherein the metal complex is a copper complex. 5. The medical device of claim 1, wherein the metal complex comprises Cyclen, Cyclam, DTTCT, or a bipyrridine ligand. 6. The medical device of claim 1, wherein the metal complex is attached to the surface of the coating. 7. The medical device of claim 1, wherein the metal complex comprises an ion selected from the group consisting of Cu.sup.2+, Co.sup.2+, Ni.sup.2+, Zn.sup.+2+, Al.sup.3+, and Fe.sup.3+. 8. A method of treating a disorder in a patient comprising implanting in the patient the medical device of claim 1, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof. 9. The medical device of claim 1, further comprising one or more biobeneficial materials selected from paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6tetramethylpiperidine-1-oxyl(4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-0-(2-hydroxy)ethyl-rapamycin(everolimus), 40-O-(3hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N 1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, c1obetasol, bioactive RGD, CD-34 antibody, abciximab (REOPRO), and progenitor cell capturing antibody.

Details for Patent 8,470,358

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-03-29